DIAアカウントをお持ちの場合、サインインしてください。

サインイン

ユーザーIDをお忘れですか? or パスワードをお忘れですか?

Virtual Event

2020年10月19日 (月) 午前 9:55 - 2020年10月20日 (火) 午後 5:30

(Eastern Standard Time)

Horsham, PA 19044

DIA Annual Canadian Meeting

Session 4 Track A: Regulatory Innovation at Health Canada: Advancing Agile Regulations for Drugs and Devices

Session Chair(s)

Judith  Mergl, MSc

Judith Mergl, MSc

Director, Regulatory Affairs and Operational Services

AbbVie Corporation, Canada

Innovative technologies are dramatically changing the health landscape. This complex, modern health environment requires new regulatory approaches to enable access to novel and innovative health technologies, while continuing to protect patient safety. In this interactive session, Health Canada leadership will discuss key projects in the Department’s Regulatory Innovation Agenda, including modernizing clinical trial regulations, enabling Advanced Therapeutic Products, pursuing agile licensing for drugs and medical devices, and advancing modernization in compliance and enforcement. In addition, the presenters will discuss lessons learned from Health Canada’s agile regulatory response to COVID-19, the impact of the pandemic on the Regulatory Innovation Agenda, and our path forward.

Learning Objective : At the conclusion of this session, participants should be able to:
  • Summarize the key pillars of Health Canada’s Regulatory Innovation Agenda
  • Explain how the Regulatory Innovation Agenda will support access to innovative health technologies
  • Describe agile regulatory measures introduced in response to COVID-19

Speaker(s)

Elizabeth  Toller, MA

Regulatory Innovation at Health Canada: Advancing Agile Regulations for Drugs and Devices

Elizabeth Toller, MA

Health Canada, Canada

Associate Director General, Policy, Planning and International Affairs Directora

Carole  Legare, MD

Regulatory Innovation at Health Canada: Advancing agile regulations for drugs and devices

Carole Legare, MD

Health Canada, Canada

Director, Office of Clinical Trials, TPD

Celia  Lourenco, PhD

Regulatory Innovation at Health Canada: Advancing Agile Regulations for Drugs and Devices

Celia Lourenco, PhD

Health Canada, Canada

Director General, Biologic and Radiopharmaceutical Drugs Directorate, HPFB

David  Boudreau

Speaker

David Boudreau

Health Canada, Canada

Director General, Medical Devices Directorate, Health Products and Food Branch

Catherine  Hudon, MPA

Speaker

Catherine Hudon, MPA

Health Canada, Canada

最新情報や機会を逃さないで

DIAのメールを購読すれば、常に最新の業界情報やイベント情報を得ることができます。